Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Sildenafil Pfizer®:Viatris Pharma GmbH
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
G04BE03 - SildenafilATC-DDD Version 2016. Source: WHO
G - Genito Urinary System and Sex Hormones
G04 - Urologicals

Antiseptic and antiinfective preparations for systemic use specifically used in urinary tract infections, see J01.
Antiinfectives for systemic use, see group J.
Gynecological antiinfectives and antiseptics, see G01.

G04B - Urologicals

This group comprises urological preparations other than antiseptics and antiinfectives.

G04BE - Drugs Used in Erectile Dysfunction

Alprostadil intracavernosal injection for treatment of erectil dysfunction is classified here, while formulations used to maintain the patency of the ductus arteriosis in neonates are classified in C01EA01.
Combinations of papaverine and phentolamine for intracavernous administration are classified under G04BE30 - combinations. Combinations of phentolamine and aviptadil (polypeptide) are classified under G04BE30 - combinations.
Phosphodisesterase inhibitors also indicated for pulmonary arterial hypertension (PAH) are classified in this group. Other agents used for treatment of PAH are classified in C02KX or in B01AC. Combinations of ambrisentan or macitentan and phosphodisesterase inhibitors are classified in C02KX - Antihypertensives for pulmonary arterial hypertension.
Combinations of alpha-adrenoreceptor antagonists or testosterone-5-alpha reductase inhibitors and phosphodisesterase inhibitors used in benign prostatic hypertrophy are classified in G04CA or G04CB, respectively.

The DDDs are based on single treatment of erectile dysfunction.

G04BE03 - Sildenafil
2023 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home